You are here

  • Home
  • Archive
  • Volume 28, Issue 3
  • BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma

Article Text

Article menu

Download PDFPDF

Ovarian Cancer
BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma
  1. Luis Felipe Sallum, MD*,
  2. Liliana Andrade, MD, PhD†,
  3. Larissa Bastos Eloy da Costa, MD, PhD†,
  4. Susana Ramalho, MD, PhD*,
  5. Amanda Canato Ferracini, Pharmacist‡,
  6. Rodrigo de Andrade Natal§,
  7. Angelo Borsarelli Carvalho Brito, MD∥,
  8. Luis Otávio Sarian, MD, PhD* and
  9. Sophie Derchain, MD, PhD*
  1. * Department of Obstetrics and Gynecology, State University of Campinas, Campinas, Faculty of Medical Sciences;
  2. † Department of Pathology, University of Campinas, Campinas, Faculty of Medical Sciences; and
  3. ‡ Program in Medical Sciences,
  4. § Laboratory of Investigative and Molecular Pathology, and
  5. ∥ Laboratory of Cancer Genetics, State University of Campinas, Campinas, Faculty of Medical Sciences, Campinas, São Paulo, Brazil.
  1. Address correspondence and reprint requests to Sophie Derchain, MD, PhD, Department of Obstetrics and Gynecology – Faculty of Medical Sciences – State University of Campinas, Rua Tessália Vieira de Camargo, 126, Zip code: 13083-970 – Campinas, São Paulo, Brazil. E-mail: fsallum{at}unicamp.br.

Abstract

Objective The purpose of this study was to compare the immunohistochemical expression of BRCA1, Ki67, and β-catenin in women with low-grade (LGSOC) and high-grade serous ovarian carcinomas (HGSOC) and their relationship with clinicopathological features, response to platinum-based chemotherapy, and survival.

Methods For this study, 21 LGSOC and 85 HGSOC stage I to IV cases, diagnosed and treated from 1996 to 2013 and followed-up until December 2016, were included. BRCA1, Ki67, and β-catenin expression was assessed using tissue microarray-based immunohistochemistry.

Results Women with HGSOC were significantly more likely to have advanced-stage disease (P < 0.001), higher CA125 levels (P < 0.001), postsurgery residual disease (P < 0.01), and higher rates of disease progression and recurrence (P = 0.001). The percentage of women with HGSOC whose tumors expressed Ki67 was significantly higher compared with women with LGSOC (P < 0.001). The expression of BRCA1 and β-catenin did not differ between LGSOC and HGSOC (P = 0.12 and P = 1.00, respectively). The clinicopathological features and the response to platinum-based chemotherapy did not differ according to the BRCA1, Ki67, and β-catenin expression in either group. In HGSOC, only International Federation of Gynecology and Obstetrics stage was independently associated with poor survival (PFS and OS).

Conclusions Ki67 expression was significantly higher in HGSOC. BRCA1 and β-catenin expression did not differ between LGSOC and HGSOC samples. BRCA1, Ki67, and β-catenin expression was neither related to clinicopathological features, response to platinum-based chemotherapy, nor survival. Only International Federation of Gynecology and Obstetrics stage remained associated with poor survival in women with HGSOC.

  • Cystadenocarcinoma
  • Serous
  • Ovarian neoplasms
  • Biomarkers
  • Survival analysis
  • Prognosis

https://doi.org/10.1097/IGC.0000000000001205

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.